Open AccessActivity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study
Author(s) -
Giuseppe Di Lorenzo,
Antonio Rea,
Chiara Carlomagno,
Stefano Pepe,
Giovannella Palmieri,
Roberto Labianca,
Antonio Chirianni,
Alfonso De Stefano,
Vincenzo Esposito,
Sabino De Placido,
Vincenzo Montesarchio
Publication year - 2007
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v13.i48.6553
Subject(s) - folinic acid , medicine , hepatocellular carcinoma , fluorouracil , gastroenterology , doxorubicin , toxicity , chemotherapy , phases of clinical research , pharmacology , surgery
To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA).